Lei Yin

Second Military Medical University — China

Medicine · Health Sciences

10h-index1.2kcitations69works1.82yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Lung Cancer Treatments and Mutations(13), Cancer Immunotherapy and Biomarkers(11), Gastric Cancer Management and Outcomes(11), Gastrointestinal Tumor Research and Treatment(9), Pancreatic and Hepatic Oncology Research(6)

Publications69 total

Supplementary Table S1 from Event-Free Survival as a Surrogate for Overall Survival in Gastric and Gastroesophageal Junction Adenocarcinoma: A Meta-analysis in the Neoadjuvant ± Adjuvant Setting
2025Open Access
SUZ12 promotes pancreatic ductal adenocarcinoma progression and chemoresistance by epigenetically silencing NCOA4-induced ferroptosis
Acta Biochimica et Biophysica Sinica·2025Open Access
A Systematic Literature Review of Real-World Treatment Effectiveness and Economic and Humanistic Burden in Patients With Muscle-Invasive Bladder Cancer Who Underwent Radical Cystectomy
ClinicoEconomics and Outcomes Research·2025Open Access
[A prospective cohort study on the association of sleep duration and fasting plasma glucose with risk of stroke].
PubMed·2025
Serum LncRNA PSMB8-AS1 as a novel biomarker for predicting acute coronary syndrome
Scientific Reports·2025Open Access
Optimization of antimicrobial peptide Smp43 as novel inhibitors of Cancer
Bioorganic Chemistry·2025· 2 cited
HER2-targeted PET/CT imaging provides potential biomarkers for differentiating HER2-zero, -low, and -positive breast cancer
European Journal of Nuclear Medicine and Molecular Imaging·2025· 3 cited
Metabolic characterization and radiomics-based composite model for breast cancer immune microenvironment types using 18F-FDG PET/CT
European Journal of Nuclear Medicine and Molecular Imaging·2025· 1 cited
Effect of multidisciplinary collaborative emergency intervention using failure mode and effect analysis model on time to bleeding detection, complication rate, and vital signs in upper gastrointestinal hemorrhage patients
World Chinese Journal of Digestology·2025Open Access
Comparative analysis of metabolic characteristics and prognostic stratification of HER2-low and HER2-zero breast cancer using 18F-FDG PET/CT imaging
Cancer Imaging·2024· 5 citedOpen Access
CO77 A Systematic Literature Review of Real-World Treatment Effectiveness and Economic and Humanistic Burden in Patients with Muscle Invasive Bladder Cancer
Value in Health·2024
Clinical outcomes of adjuvant nivolumab in resected stage III melanoma: comparison of CheckMate 238 trial and real-world data
Cancer Immunology Immunotherapy·2024· 3 citedOpen Access
Contrast-enhanced CT in the differential diagnosis of bladder cancer and paraganglioma
Abdominal Radiology·2024· 2 cited
Black phosphorus-based nanoparticles induce liver cancer cell mitochondrial apoptosis and immune cell tumor infiltration for enhancing dendritic cell therapy
Heliyon·2024· 9 citedOpen Access
Efficacy and pharmacoeconomic advantages of Fufang Huangbai Fluid hydropathic compress in diabetic foot infections: a comparative clinical study with antimicrobial calcium alginate wound dressing
Frontiers in Pharmacology·2024· 3 citedOpen Access
Fragmentomics of cell-free DNA as a sensitive biomarker for early detection of pancreatic cancer
HPB·2024· 1 citedOpen Access
64O Lenvatinib plus pembrolizumab, pemetrexed, and a platinum (len + pembro + chemo) as first-line therapy for metastatic non squamous non-small cell lung cancer (NSCLC): Phase III LEAP-006 study
Immuno-Oncology Technology·2023· 5 citedOpen Access
138MO Pembrolizumab (Pembro) or placebo (Pbo) plus chemotherapy (Chemo) for advanced HER2-negative gastric/gastroesophageal junction (G/GEJ) adenocarcinoma (KEYNOTE-859): Asia subgroup analysis
Annals of Oncology·2023· 1 cited
O-3 Additional data from the KEYNOTE-859 study of pembrolizumab plus chemotherapy versus placebo plus chemotherapy for advanced HER2-negative gastric or gastroesophageal junction (G/GEJ) cancer
Annals of Oncology·2023· 5 citedOpen Access
Supplementary Table S1 from Event-Free Survival as a Surrogate for Overall Survival in Gastric and Gastroesophageal Junction Adenocarcinoma: A Meta-analysis in the Neoadjuvant ± Adjuvant Setting
2023Open Access
page 1 of 4Next →

Frequent Co-authors

Ping Yan(8), Meng Liu(7), Jipan Xie(7), Pooja Bhagia(7), Zev A. Wainberg(6), Adriana Valderrama(6), Shujing Zhang(6), Chie‐Schin Shih(6), Qianqian Gu(6), Kohei Shitara(6), Yelena Y. Janjigian(6), Josep Tabernero(6), Rong Fu Wang(5), Qian Zhao(5), Keith A. Betts(4), Rongfu Wang(4), Lei Kang(4), Chunli Zhang(4), Paul L. Nguyen(3), Xiangmei Gu(3)